| 1 |
34117374 | Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation. | 2021 Jun 11 |
3 |
| 2 |
34944800 | Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. | 2021 Dec 8 |
2 |
| 3 |
30587441 | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. | 2019 Mar |
1 |
| 4 |
28960265 | Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. | 2018 Jan 15 |
3 |
| 5 |
29662541 | Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. | 2018 Mar |
1 |
| 6 |
29727493 | Erratum: Fathi AT, Blonquist TM, Hernandez D, et al. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018;124:306-314. | 2018 May 15 |
1 |
| 7 |
30069760 | Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. | 2018 |
1 |
| 8 |
30514344 | FLT3 inhibitors in acute myeloid leukemia. | 2018 Dec 4 |
1 |
| 9 |
27842445 | Cabozantinib in genitourinary malignancies. | 2017 Apr |
1 |
| 10 |
28703624 | Cabozantinib in the treatment of hepatocellular carcinoma. | 2017 Sep |
1 |
| 11 |
26536165 | Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. | 2016 |
2 |
| 12 |
27060207 | Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). | 2016 Jul 1 |
7 |
| 13 |
26152149 | Cabozantinib in Thyroid Cancer. | 2015 |
1 |
| 14 |
24756794 | Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. | 2014 |
1 |
| 15 |
21926191 | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. | 2011 Dec |
2 |